A Multi-center, Observational, Non-interventional, Post-authorisation Safety Study of Patients with Relapsed/Refractory Multiple Myeloma in European Union.

Trial Profile

A Multi-center, Observational, Non-interventional, Post-authorisation Safety Study of Patients with Relapsed/Refractory Multiple Myeloma in European Union.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary) ; Thalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms EU PASS
  • Most Recent Events

    • 25 Jun 2017 Results (n=3630, data cut off March 1, 2016) presented at the 22nd Congress of the European Haematology Association
    • 06 Dec 2016 Results (n=218) assessing the safety of Pomalidomide, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 According to the abstract presented at the 58th Annual Meeting and Exposition of the American Society of Hematology 2016, 3632 patients across 17 European countries were included in this study as of June 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top